April 09, 2026

Marriage as a Marker of Cancer Risk?

Never-married adults show markedly higher cancer incidence. A large population study asks why marital status remains a footnote in risk frameworks.

Conexiant

April 08, 2026

FDA Clears At-Home HPV Screening Tool

Self-collection approach aims to expand screening access

Conexiant

April 06, 2026

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Conexiant

April 06, 2026

Hidden Pain After Mastectomy?

Chronic postsurgical pain affects many patients but is often underdiagnosed and undertreated.

KFF Health News

March 26, 2026

Obesity’s Cancer Role Underestimated

A proposed framework highlights potential sources of bias in current estimates

Conexiant

March 24, 2026

How the Outlook on Fertility Preservation for Patients With Cancer Is Improving

Each year in the United States, about 90,000 adolescents and young adults (AYAs), ages 15 to 39, are diagnosed with cancer,1 and they are immediately faced with myriad challenges and disruptions in th...

The ASCO Post

March 18, 2026

HPV Vaccine Delays Persist in Teens

Missed opportunities for HPV vaccination before sexual debut remain common, with practice variation and timing influencing uptake

Conexiant

March 11, 2026

Perceptions of Quality of Life for Women Pregnant During a Cancer Diagnosis: A Review of the Literature

The rising trend of delaying childbirth among women has critical implications for cancer diagnoses during pregnancy, shedding light on overlooked QOL concerns.

JADPRO

October 17, 2023

Can Younger Women With Hormone Receptor–Positive Breast Cancer Safely Pause Endocrine Therapy to Pursue Pregnancy?

Preserving fertility is a driving concern for many young women with breast cancer. Many of these women have hormone receptor–positive breast cancer and are treated with adjuvant endocrine therapy for ...

The ASCO Post

September 17, 2021

Expert Point of View: Thomas Herzog, MD

Dr. Thomas Herzog discusses the fuzuloparib abstract, its implications, and safety profile, providing valuable insights into PARP inhibitors in ovarian cancer.

The ASCO Post